Search PubMed⌕ Search

Biomedical subjects

S Janicki

Publications and source records attributed to S Janicki.

49 records · Page 3Linked to original sources
PubMed1987

Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN).

An oral therapeutic system can only be effective for soluble drugs. If no suitable salt of a drug can be found, then an osmotic agent such as sodium chloride or mannitol has to be used in a modified two-chamber system, or the osmotic dispenser with collapsible supply container. A one-chamber gastrointestinal therapeutic system (GTS) is proposed which is capable of delivering insoluble drug at a relatively constant rate. The unit consists of a tablet containing the insoluble drug and the soluble carrier, surrounded by a rate-controlling membrane with a delivery orifice. If the unit is in contact with fluid, water will pass constantly through the membrane into the tablet, dissolve the carrier which will be pumping out the insoluble drug through the delivery orifice. The effect was studied of variable content and weight of the tablet, size of the delivery orifice and thickness of the membrane on the rate of insoluble drug release from the GTS.

Excipients↗
PubMed1985

[Bilateral-velour blood vessel prostheses produced by the Center for Research and Development of the Textile Industry (TRICOMED) in Lódź. Personal experiences].

Two-year observations on 17 patients after the implantation of bilaterally velour vascular prostheses were made. In the postoperative course 5 prostheses underwent occlusion. Special attention was given to the behaviour of the prostheses above and below the knee-joint. The velour vascular prostheses made by the Research Centre Tricomed in Lódź could be a good alternative to other grafts in the surgical treatment of occlusion located in the above knee but in occlusions below the knee they can be used only exceptionally.

Aged↗
PubMed1982

[Barbital buffer in tablets as a solvent for complement fixation test (CFT)].

The purpose of this paper was to develop a tableting technology of barbital buffer as a standard diluent easy in use for complement fixation test (CFT). As starting point, barbital (veronal) buffer after Alton et al. [1] was assumed. Among 4 solubilizers polyvinyl pyrrolidone (PVP 10 000) was chosen, which provided a good solubility of the barbital in distilled water at 20 degrees C and it affected favourably the complement activity (C'). PVP 10 000 added to the components of barbital buffer at an amount of 0.275 per 10 tablets, in the form of solution for granulation, provided the required physical properties of the tablets. As compared with the barbital buffer after Alton et al. [1], the tablets produced affected favourably C' activity, decreased the range of spontaneous haemocyte lysis, and they did not effect CFT titers of two anti-Brucella abortus standard sera as well as 77 sera of cattle infected with brucellosis under natural conditions. The described physical and biological properties of the barbital buffer tablets with PVP addition indicate their usability as diluent for CFT. A standard diluent used in the form of tablets in all Poland's laboratories should provide a better reproducibility of CFT results in diagnostic examinations towards brucellosis as well as other infectious diseases in men and animals.

Animals↗
PubMedDate not supplied

In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug.

Submicron emulsions containing 2.0% w/v pilocarpine as pilocarpine HCl, soybean oil (10% w/v) and egg lecithin (1.2% w/v) were formulated. Emulsions at pH 5.0, 6.5 and 8.5 were applied to the rabbit's eye, and the reduction in pupil diameter was measured for 6 h. The miotic effect was compared with that obtained with aqueous solutions at the same pH. A prolonged miotic effect was observed when the submicron emulsion was used as a vehicle. After application of emulsions at pH 5.0, 6.5 or 8.5, the time when 20% reduction of pupil diameter was still observed was 3.9 +/- 1.1 h, 4.3 +/- 1.3 h and 5.3 +/- 0.8 h, respectively, while, after application of a solution, this parameter was shorter by 30-40%. AUC(0-6h) values were larger after application of the submicron emulsions in comparison to aqueous solutions; however, statistically significant differences were only observed for emulsions at pH 6.5. Although the bioavailability of the drug is pH dependent, emulsions at higher pH cannot be considered for clinical use because of pilocarpine degradation which occurs with a similar rate as in aqueous solutions. Introduction of pilocarpine into the oily phase in the form of pilocarpine base or its oleate did not improve either the physicochemical or the pharmacological properties of the formulations. Irrespective of the pH and chemical form of pilocarpine used for emulsion preparation, practically all drug was found in the aqueous phase of the emulsion; thus, partitioning to the oily phase was negligible.

Animals↗
PubMedDate not supplied

Investigation of diazepam lipospheres based on Witepsol and lecithin intended for oral or rectal delivery.

Diazepam was incorporated in lipospheres prepared by high pressure homogenization of melted Witepsol (10%) dispersed in aqueous lecithin (2.4%). Diazepam content was 0.4% and more than 98% of the dose was found to be encapsulated in the lipospheres. Although the initial mean particle size was 0.3 micron, the liposhperes agglomerated during storage and this phenomenon was not eliminated by increasing lecithin concentration to 4% or incorporation of oleic acid (0.1%) and co-surfactants, polysorbate 80 (0.5%) or poloxamer (up to 6%). The formulation was not able to mask effectively bitter taste of diazepam, even when lipids of higher melting temperature, namely glyceryl tripalmitate or stearic acid, were introduced.

Administration, Oral↗